FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2797416317> ?p ?o ?g. }

• W2797416317 abstract "Objective: To determine the frequency of antibodies to neuronal surface antigens (NSA-abs) in patients with possible autoimmune encephalitis (AE) or new-onset refractory status epilepticus (NORSE). Background: The frequency of NSA-abs in patients with possible AE or NORSE is unknown. Design/Methods: Patients seen between January 1, 1999 and August 31, 2016, with criteria (Lancet Neurol 2016;15:391–404) for possible AE (n=98), were included. Clinical information was reviewed and antibody testing was performed. One autopsied case of NORSE not examined for NSA-abs was included. Outcome was compared between patients with features of NORSE and those with NSA-abs. Results: NSA-abs were identified in 38 of 98 (39%) patients with possible AE, including NMDA receptor (NMDAR)-abs (n=32), AMPAR-abs (n=3), LGI1-abs (n=2), GABAbR-abs (n=2), and antibodies not characterized yet (n=2); two patients had multiple NSA-abs. Twenty-seven of the 38 patients with NSA-abs responded to immunotherapies, and 28 (74%) ultimately recovered at the median follow-up (29 months; range, 1–179). Eleven of 98 (11%) patients had features of NORSE, and none had NSA-abs. Patients with NORSE presented with status epilepticus following fever, and were highly refractory to conventional antiepileptic treatment and first-line immunotherapies, but 3 of 5 patients treated responded to intravenous cyclophosphamide. Only 3 of 12 (25%) patients with NORSE recovered considerably but still had seizures frequently at the median follow-up (10 months; range, 3–84). Initial brain MRI in patients with NORSE was unremarkable, but follow-up MRIs in 9 of 11 patients showed symmetric T2/FLAIR hyperintensities in the hippocampus, amygdala, insula, claustrum, thalamus, and perisylvian operculum. In 10 of 12 (83%) patients brain atrophy developed. The autopsy of one case of NORSE showed nonspecific hippocampal pathology. Conclusions: NSA-abs were detected in 39% of patients with possible AE; 74% of these patients improved. In contrast, patients with NORSE did not have NSA-abs, were refractory to immunotherapies, and more frequently had poor outcome. Disclosure: Dr. Iizuka has received research support from Mitsubishi Tanabe Pharma Corporation. Dr. Kaneko has nothing to disclose. Dr. Tominaga has nothing to disclose. Dr. Kanazawa has nothing to disclose. Dr. Ugawa has received personal compensation for activities with CHUGAI-IGAKUSHA, Igaku-Shoin Ltd, Medical View Co. Ltd., and Blackwell Publishing K.K. Dr. Ugawa has received research support from Taiwan Movement Disorders Society, Chinese Neurology Society, Astellas Pharma Inc., Eisai Co., Ltd., FP Pharmaceutical Corporation, Otsuka Pharmaceutical Co., Ltd., Elsevier Japan K. K., KISSEI PHARMACEUTICAL CO., Ltd. Dr. Hara has nothing to disclose. Dr. Onozawa has nothing to disclose. Dr. Asari has nothing to disclose. Dr. Hata has nothing to disclose. Dr. Kaneko has nothing to disclose. Dr. Yoshida has nothing to disclose. Dr. Sugiura has nothing to disclose. Dr. Ugawa has received royalties from CHUGAI-IGAKUSHA, Igaku-Shoin Ltd, Medical View Co. Ltd., and Blackwell Publishing K.K. Dr Ugawa has received research support from Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan, and the Support Center for Advanced Telecommunications Technology Research. Dr. Watanabe has nothing to disclose. Dr. Tomita has nothing to disclose. Dr. Kosakai has nothing to disclose. Dr. Kaneko has nothing to disclose. Dr. Ishima has nothing to disclose. Dr. Kitamura has nothing to disclose. Dr. Dalmau receives royalties from the editorial board of Up-To-Date. Dr. Dalmau has received royalties from a patent from Memorial Sloan-Kettering Cancer Center and royalty payments and/or for technology and invention on NMDAR, GABA(B), GABAaR, DPPX, and IgLON5 antibody test. Dr. Dalmau has received research support from Euroimmun. Dr. Nishiyama has nothing to disclose." @default.
• W2797416317 created "2018-04-24" @default.
• W2797416317 creator A5002605322 @default.
• W2797416317 creator A5007755064 @default.
• W2797416317 creator A5008042009 @default.
• W2797416317 creator A5009165182 @default.
• W2797416317 creator A5021977238 @default.
• W2797416317 creator A5026355605 @default.
• W2797416317 creator A5028379946 @default.
• W2797416317 creator A5034149246 @default.
• W2797416317 creator A5037677443 @default.
• W2797416317 creator A5040602448 @default.
• W2797416317 creator A5046682439 @default.
• W2797416317 creator A5053426336 @default.
• W2797416317 creator A5053739464 @default.
• W2797416317 creator A5053919172 @default.
• W2797416317 creator A5055217545 @default.
• W2797416317 creator A5058551066 @default.
• W2797416317 creator A5058619540 @default.
• W2797416317 creator A5063343308 @default.
• W2797416317 creator A5071195473 @default.
• W2797416317 creator A5082406480 @default.
• W2797416317 creator A5084681164 @default.
• W2797416317 date "2017-04-18" @default.
• W2797416317 modified "2023-10-07" @default.
• W2797416317 title "Antibodies to neuronal surface antigens in possible autoimmune encephalitis and new-onset refractory status epilepticus (NORSE) (S21.007)" @default.
• W2797416317 hasPublicationYear "2017" @default.
• W2797416317 type Work @default.
• W2797416317 sameAs 2797416317 @default.
• W2797416317 citedByCount "0" @default.
• W2797416317 crossrefType "journal-article" @default.
• W2797416317 hasAuthorship W2797416317A5002605322 @default.
• W2797416317 hasAuthorship W2797416317A5007755064 @default.
• W2797416317 hasAuthorship W2797416317A5008042009 @default.
• W2797416317 hasAuthorship W2797416317A5009165182 @default.
• W2797416317 hasAuthorship W2797416317A5021977238 @default.
• W2797416317 hasAuthorship W2797416317A5026355605 @default.
• W2797416317 hasAuthorship W2797416317A5028379946 @default.
• W2797416317 hasAuthorship W2797416317A5034149246 @default.
• W2797416317 hasAuthorship W2797416317A5037677443 @default.
• W2797416317 hasAuthorship W2797416317A5040602448 @default.
• W2797416317 hasAuthorship W2797416317A5046682439 @default.
• W2797416317 hasAuthorship W2797416317A5053426336 @default.
• W2797416317 hasAuthorship W2797416317A5053739464 @default.
• W2797416317 hasAuthorship W2797416317A5053919172 @default.
• W2797416317 hasAuthorship W2797416317A5055217545 @default.
• W2797416317 hasAuthorship W2797416317A5058551066 @default.
• W2797416317 hasAuthorship W2797416317A5058619540 @default.
• W2797416317 hasAuthorship W2797416317A5063343308 @default.
• W2797416317 hasAuthorship W2797416317A5071195473 @default.
• W2797416317 hasAuthorship W2797416317A5082406480 @default.
• W2797416317 hasAuthorship W2797416317A5084681164 @default.
• W2797416317 hasConcept C118552586 @default.
• W2797416317 hasConcept C126322002 @default.
• W2797416317 hasConcept C142424586 @default.
• W2797416317 hasConcept C159654299 @default.
• W2797416317 hasConcept C163764329 @default.
• W2797416317 hasConcept C203014093 @default.
• W2797416317 hasConcept C2522874641 @default.
• W2797416317 hasConcept C2777341932 @default.
• W2797416317 hasConcept C2778186239 @default.
• W2797416317 hasConcept C2781460105 @default.
• W2797416317 hasConcept C71924100 @default.
• W2797416317 hasConcept C83455156 @default.
• W2797416317 hasConcept C86803240 @default.
• W2797416317 hasConcept C87355193 @default.
• W2797416317 hasConceptScore W2797416317C118552586 @default.
• W2797416317 hasConceptScore W2797416317C126322002 @default.
• W2797416317 hasConceptScore W2797416317C142424586 @default.
• W2797416317 hasConceptScore W2797416317C159654299 @default.
• W2797416317 hasConceptScore W2797416317C163764329 @default.
• W2797416317 hasConceptScore W2797416317C203014093 @default.
• W2797416317 hasConceptScore W2797416317C2522874641 @default.
• W2797416317 hasConceptScore W2797416317C2777341932 @default.
• W2797416317 hasConceptScore W2797416317C2778186239 @default.
• W2797416317 hasConceptScore W2797416317C2781460105 @default.
• W2797416317 hasConceptScore W2797416317C71924100 @default.
• W2797416317 hasConceptScore W2797416317C83455156 @default.
• W2797416317 hasConceptScore W2797416317C86803240 @default.
• W2797416317 hasConceptScore W2797416317C87355193 @default.
• W2797416317 hasLocation W27974163171 @default.
• W2797416317 hasOpenAccess W2797416317 @default.
• W2797416317 hasPrimaryLocation W27974163171 @default.
• W2797416317 hasRelatedWork W1972577665 @default.
• W2797416317 hasRelatedWork W2909815363 @default.
• W2797416317 hasRelatedWork W2955228231 @default.
• W2797416317 hasRelatedWork W2966670328 @default.
• W2797416317 hasRelatedWork W3087592004 @default.
• W2797416317 hasRelatedWork W3200785709 @default.
• W2797416317 hasRelatedWork W3203290822 @default.
• W2797416317 hasRelatedWork W3214733602 @default.
• W2797416317 hasVolume "88" @default.
• W2797416317 isParatext "false" @default.
• W2797416317 isRetracted "false" @default.
• W2797416317 magId "2797416317" @default.
• W2797416317 workType "article" @default.